Investigating the in-vitro release properties of triamcinolone acetonide injectable suspension from a drug-eluting balloon-like spacer for the treatment of paranasal sinusitis

Anna Externbrink, Carmen Liermann, Christian Scharf, Sandra Klein
University of Greifswald, Germany
annatexternbrink@uni-greifswald.de

Purpose
The drug-eluting balloon-like MicroFlow Spacer has recently been introduced to be used with steroids for the treatment of chronic paranasal sinusitis. The spacer is FDA approved to be used with saline. The use with triamcinolone acetonide is currently considered off-label [1,2]. After implantation into the sinus the device is filled with triamcinolone acetonide injectable suspension and allows the substance to elute from an expandable reservoir, containing multiple laser-cut-openings over a sustained period of time (up to 24-28 days). The scope of this study was to investigate the in-vitro release properties of a MicroFlow Spacer. The recirculating holder apparatus (USP7) was utilized for this purpose. To understand the mechanisms that facilitate drug elution from the balloon, additional release experiments were performed with the suspension in a dialysis bag.

Methods
Drug release was evaluated in a small volume USP apparatus 7 (400-D5 Agilent Technologies), the recirculating holder, equipped with 10 mL dialysis cells (Fig. 2). In all experiments the test temperature was 37°C. Automated sampling and media replacement was performed via a port at the bottom of the dissolution cell. To ensure sink conditions in the outer compartment the release medium was completely replaced with sampling. Analytical quantification was performed using HPLC-UV-AAS (Column: RP-8 4.6x50 mm, 5 μm, Mobile phase: 65/35 Methanol/NH₄NO₃ (N,N), Flow rate: 1 mL/min, Detection wavelength 238 nm). After each study the residual drug content in either dialysis bag or balloon was determined.

Dialysis bag
For the experiments with the dialysis bag TriamHexal® injectable suspension (Hexal AG), containing 40 mg/mL triamcinolone acetonide was injected into a dialysis tube with defined length that was then sealed with a nylon strand and a recirculating holder (Fig. 3). Two different membranes (both from Spectrum Laboratories, Inc.) were used:
- Spectra/Por® 7 (regenerated cellulose) with a MWCO of 25,100 and a flat width of 6 mm
- Spectra/Por® CE (cellulose ester) with a MWCO of 500 and a flat width of 12.1 mm

Experiments were performed in phosphate buffered saline pH 7.4 (PBS) with different concentrations of sodium dodecyl sulfate (SDS), added injection volumes and dialysis speeds were varied.

Drug-eluting balloon
The MicroFlow Spacer (Fig. 4) consists of a catheter shaft with an expandable reservoir (Fig. 5) which is mounted on the distal shaft portion of the device. The spacer is implanted into the involved sinus and filled with a therapeutic agent via the Luer Hub connector through the proximal shaft portion causing the reservoir to expand in situ (i.e. one way valve prevents backflow). Therewith the catheter is trimmed to the desired implantated length. A Balloon Catheter MicroFlow Spacer for the frontal sinus (product code BSC147PS, Lot No: 1302032, Arclancent, Inc.) was used for the in-vitro study. A clinically relevant dose of 10 μL of TriamHexal 40 mg was infused with an 1 mL syringe. Since the capacity of the device does not hold the entire dose a small amount of the suspension is pressed through the laser-cut-openings of the reservoir upon injection. Subsequently, the proximal shaft of the device (Fig. 4, indicated by arrow bar) was cut away. To prevent the suspension to leak from the distal end of the shaft and to assure that all suspension that is located in the reservoir is assessed during the dissolution study the distal end was sealed with an instant adhesive. The adhesives was allowed to dry for at least half an hour. To prevent degradation of the suspension in the reservoir in the intervening period, the balloon was placed in an Eppendorf vial containing a defined amount of suspension throughout the preparation process. To avoid sedimentation of the suspension the vials were gently shaken while the adhesives was allowed to dry. After half an hour the balloon was removed from the vial, wiped clean and placed in a mesh basket holder (Fig. 3). Dissolution studies were performed in PBS containing 0.3 % SDS and the dialysis speed was set at 20 rpm.

Results
Figures 6-9 show the release profiles from experiments with the dialysis bag under different test conditions. Overall, drug release was sustained and increased with increasing concentration of surfactant (Fig. 6). Dissolution studies with the plain suspension in the Felleddo apparatus under sink condition without coving (adequate agitation) showed comparatively fast dissolution in PBS within 30 minutes. The dissolution was significantly improved when coving was observed (data not shown). Drug release from the dialysis bag was independent of the applied dialysis speed (Fig. 7) which can be explained by poor hydrodynamics conditions inside the dialysis bag (drug particles accumulated at the bottom of the dialysis bag). Figure 8 shows that small variations in the membrane flat width and the por size (which is related to the molecular weight cut off (MWCO) of the membrane) did not affect drug release. Drug release from the spacer (shown in Figure 9) also shows decreased variation compared to the dialysis bag. In the same graph, the present test conditions drug release from the spacer was somewhat faster when compared with the dialysis bag. The release rate is linearly higher and decreases with time (with a steep gradient over the first part of the curve).

Discussion
Experiments with the suspension in a dialysis bag indicate that drug release is controlled by poor hydrodynamics and low solubility inside the dialysis bag, i.e. that slow dissolution of the turbidresinibility inside the dialysis bag is the rate limiting step. Only dissolved particles are being released from the dialysis bag. In comparison, the balloon has multiple laser-cut-openings also allowing elution of undissolved particles. In a first experiment with the balloon the drug release was initially higher when compared with the dialysis bag. It is possible that in the early stage undissolved drug particles are washed out through the balloon openings facilitated by pressure or gravity. However, hydrodynamics inside the balloon are poor and sedimentation of undissolved particles could also be observed in the balloon experiment. It is therefore likely that the initial burst is followed by diffusion washout of undissolved drug remaining in the reservoir; thereby providing sustained release over an extended period of time. We believe that drug release in this later phase is influenced by similar parameters as observed for the suspension in a dialysis bag, however, for a representative characterization of the in vitro release properties additional release experiments with the balloon are required. Also, it should be taken into account that for adequate assessment of drug function in the initial phase the preparation of the balloon-inlet might play a critical role.

Acknowledgement:
Support from Agilent Technologies and the Clinic and Polyclinic for ear, throat and nose diseases, head and neck surgery of the University of Greifswald for providing USP apparatus 7 and the MicroFlow Spacers is gratefully acknowledged.

References:

27th AAPS Annual Meeting and Exposition, November 10-14, 2013, San Antonio, TX, USA